Cigna (CI) files 8-K on Q4 and full-year 2025 results press release

Rhea-AI Filing Summary

The Cigna Group filed a current report to note that it issued a press release on February 5, 2026, covering its results for the three months and year ended December 31, 2025. The press release is attached as Exhibit 99.1 and is treated as furnished, not filed, under securities laws.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false0001739940NYSE00017399402026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 5, 2026

The Cigna Group

(Exact name of registrant as specified in its charter)

Delaware	001-38769	82-4991898
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

900 Cottage Grove Road

Bloomfield, Connecticut 06002

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:

(860) 226-6000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $0.01	CI	New York Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 5, 2026, The Cigna Group issued a press release announcing results for the three months and year ended December 31, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated February 5, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THE CIGNA GROUP
Date: February 5, 2026	By:	/s/ Ann M. Dennison
		Ann M. Dennison
		Executive Vice President and Chief Financial Officer

FAQ

What did The Cigna Group (CI) disclose in this 8-K filing?

The Cigna Group disclosed that it issued a press release announcing results for the three months and year ended December 31, 2025. That press release is attached as Exhibit 99.1 and incorporated by reference.

What period do The Cigna Group (CI) results in the press release cover?

The press release announced The Cigna Group’s results for the three months and year ended December 31, 2025. These time periods align with its fourth-quarter and full-year 2025 financial performance.

How is The Cigna Group’s Exhibit 99.1 treated under securities laws?

Exhibit 99.1, the February 5, 2026 press release, is treated as furnished rather than filed under Section 18 of the Exchange Act. This limits certain legal liabilities compared with information formally filed.

Who signed The Cigna Group (CI) 8-K dated February 5, 2026?

The 8-K was signed on behalf of The Cigna Group by Ann M. Dennison, who serves as Executive Vice President and Chief Financial Officer. Her signature authorizes the company’s submission of the report.

What exhibits are included with The Cigna Group (CI) February 5, 2026 8-K?

The filing includes Exhibit 99.1, a press release dated February 5, 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL. These exhibits provide supporting disclosure and data.

Is the February 5, 2026 Cigna press release incorporated into other SEC filings?

The press release is not automatically incorporated into other Securities Act or Exchange Act filings. It is only incorporated where a future filing expressly references it with specific incorporation language.